The major regulatory factors in the mesenteric circulation include general hemodynamic forces, the autonomic nervous system, circulating vasoactive substances, tissue metabolites and intrinsic characteristics of vascular smooth muscle. During mesenteric ischemic states smooth muscle spasm elevates resistance to blood flow and aggravates intestinal tissue hypoxia leading to mucosal necrosis. Close intraarterial infusion of potent vasodilator drugs holds the promise of reversing intestinal ischemia and preserving viability of the gut.
II from the kidneys and vasopressin from the posterior pituitary. These agents reduce blood flow to the viscera.
Closer to the blood vessels themselves are the parenchymal cells of the splanchnic organs-hepatocytes, enterocytes, secretory cells of the gastric mucosa and pancreas, visceral muscle and endocrine cells, and the many other cell types which metabolize actively in this region. As cells metabolize they change the chemical environment in which nearby blood vessels exist by lowering the partial pressure of oxygen, increasing C02 and producing de novo metabolites: nucleotides, such as cyclic AMP and ATP; polypeptides, like bradykinin; amines, e.g., histamine; and fatty acid derivatives, i.e., prostaglandins. Cells also can alter the composition of electrolytes around the blood vessels by increasing interstitial potassium and magnesium concentrations. These metabolic changes relax arteriolar smooth muscle, reduce vascular resistance and increase blood flow to the cells to support metabolic activity.
Certain properties of some splanchnic vessels play a role in controlling blood flow. One of these properties is termed "autoregulation" and is best seen in the mesenteric circulation. Autoregulation may be defined as the intrinsic ability of a regional circulation to maintain a steady blood flow in the face of fluctuating arterial blood pressure. Thus, for example, during hemorrhagic shock in which arterial hypotension occurs, blood flow is maintained near normal levels for some time in organs which exhibit autoregulation-the brain, heart, kidneys and small intestine.
"Escape" is another property of the hepatic and mesenteric vasculature. Escape occurs during continuous sympathetic nervous stimulation or infusion of catecholamines [3] . Initially blood flow to the gut declines but then recovers in a matter of minutes to control values despite continuous constrictor input from sympathetic nerves or norepinephrine. The survival value of autoregulation and escape should be apparent, since organs require a steady flow of blood to sustain metabolically dependent functions.
Less favorable features also occur in the splanchnic vasculature. Without altering total blood flow to a hollow organ of the digestive tract, sympathetic stimulation can redistribute the flow by decreasing mucosal perfusion and increasing blood flow to the muscularis of the wall. This is an adverse characteristic of the system during ischemic states because the mucosa is metabolically more active than the muscle layer and is more vulnerable to the destructive effects of a compromised blood supply.
The oxygen counter current exchanger is another feature of the mesenteric microcirculation which must be viewed as a mixed blessing [2] . Coursing down the core of each intestinal mucosal villus is an inflow arteriole and an outflow venule. These vessels carry blood to and from the capillaries of the tip of the villus. The arteriole and venule are 10-20 micra apart; these vessels run counter current to one another and have different concentrations of physically dissolved oxygen in their blood. Since oxygen is lipid soluble, this gas can diffuse out of arteriolar blood across the lipid membranes of the intervening vessels and enter venous blood draining away from the villus. The result is a lower partial pressure of oxygen at the tip of the villus than is found at the base which may contribute to the rapid turnover cycle of surface epithelial cells which die and are sloughed at the tip of the villus. During ischemic states the flow of blood is slowed through villus vessels, thereby increasing the opportunity for counter-current exchange of oxygen from inflow to outflow vessels. This shunting of oxygen away from capillaries at the tip of the villus further compounds the hypoxia of the region and is responsible for the observation of the pathologist that tissue necrosis invariably commences at the tip of the villus in severe intestinal ischemic states.
PATHOPHYSIOLOGY OF MESENTERIC ISCHEMIA AND DILATOR THERAPY
The events which transpire during fatal intestinal ischemia are depicted in Fig. 1 [4] . The typical patient is elderly, is suffering from congestive cardiac failure and is being treated with cardiac glycosides. The patient sustains an acute abdominal crisis characterized by severe pain and is taken to a hospital. Often the patient is found to be in a state of circulatory shock upon admission. The systemic arterial hypotension of shock prompts release of circulating constrictor agents-catecholamines, angiotensin II and vasopressin-and activates sympathetic nervous discharge. The fall in arterial pressure also induces collapse of microcirculatory vessels as their critical closing pressure is reached. The diminshed cardiac output in shock leads to a slowing of blood flow throughout the body with microthrombi forming, especially in venules. As the velocity of flowing blood slows, its viscosity rises. Protracted shock states lead to acidosis. Sympathetic activity redistributes blood flow away from the mucosa into the muscularis of the gut. Mucosal ischemia leads to hypoxia of the tissue which is aggravated by acidosis and by the oxygen counter-current exchanger mechanism of the villus. Necrosis ensues beginning at the tip of the villi. The necrotic mucosa fails to contain toxic materials in its lumen and there is absorption into the dying circulation of such materials as bacterial endotoxins, cellular debris, lysosomal hydrolases and cathepsins, and electrolytes. Superimposition of a profound toxemia upon intestinal ischemia and shock in an elderly patient in heart failure is intolerable. Reported mortality rates for severe intestinal ischemia hover around 100%.
Recently Siegelman et al. reported some success in the use of intraarterial vasodilator therapy in intestinal ischemic states [5] . The agent they chose was papaverine. Since many dilator drugs are known, it is of more than academic interest to consider the minimal but essential criteria for an effective drug to counteract intestinal ischemic disease. The agent should be a potent vasodilator which relaxes both arteriolar smooth muscle and precapillary smooth muscle. The arterioles are the major resistance vessels of the mesenteric circulation and their relaxation will result in augmented blood flow to the gut. The precapillary sphincters control perfusion through the vessels across which the exchange of oxygen from blood to cells must take place. Relaxation of these sphincters increases availability of oxygen and increases oxygen uptake.
Another essential property of an effective vasodilator drug is that of selectivity. It is requisite that normal blood flow be reestablished in ischemic gut by relaxation of this constricted circulation. However, if the drug relaxes smooth muscle in all peripheral circulations, it will become impossible for the heart to maintain a normal driving head of pressure to propel the blood to the tissues including the intestine. Thus, the drug must not induce a fall in systemic arterial pressure when it is dilating the mesenteric circulation. To avoid this untoward effect the drug can be infused directly into the mesenteric artery via an intraarterial catheter in minute amounts. Since the drug must be infused for a long period to break up the vasospasm and sustain blood flow at levels compatible with survival of the gut, there is danger of accumulating sufficient quantities of the drug in the general circulation to depress systemic arterial blood pressure. To avoid the depressor effect and limit the vasodilator action to the mesenteric circulation during intraarterial infusion, an effective drug would be one which is rapidly degraded by the tissues of the gut, blood, liver and lung into an inactive metabolite.
Other desirable features of an effective vasodilator agent would include its interfer- ence with various steps in the pathophysiological responses of intestinal tissue to the ravages of ischemia. During prolonged ischemic disease the gut is subjected to damage by lysosomal hydrolases and cathepsins. Stasis of blood in the intestinal vasculature predisposes to the development of microthrombi which further impede the flow of blood through the tissue. An effective drug should stabilize lysosomal membranes and oppose formation of microthrombi. In order to compare the efficacy of various candidate agents which might be effective in treating mesenteric ischemia, it is necessary to use experimental models. The intestinal circulation of an animal can provide the initial testing ground on which favorable or adverse characteristics of dilator drugs may be discovered. The finding of a significant pharmacological property in the canine mesenteric vasculature does not mean that this feature will necessarily appear with use of the drug in the intestinal vessels of subhuman primates or in the patient. This consideration does not, however, justify neglect of suitable experimental testing of agents before their new use in desperately sick patients simply because the drug is available and there is little to lqse.
At the present time it is fairly easy to estimate effect of intraarterially infused drugs on mesenteric blood flow, systemic arterial and portal venous pressures, and the arteriovenous oxygen gradient in experimental animals.
Intestinal blood flow can be measured in the laporatomized and anesthetized animal without violating the integrity of the arterial vessel. Implantation of a cufftype electromagnetic blood flow transducer and occlusive zeroing device permit the continuous measurement of superior mesenteric artery blood flow. Via catheters connected to strain gauge transducers, systemic arterial and portal venous pressures can be determined. Siphoning of a small portion of systemic arterial and portal venous blood flow into the cuvettes of a spectrophotometric arteriovenous oxygen analyzer allows measurement of the transintestinal oxygen gradient. From such measurements one can calculate mesenteric vascular resistance and intestinal oxygen consumption [6] .
Using a canine preparation in which the preceding measurements and calculations were obtained during continuous intraarterial infusion of papaverine, we found that this drug exhibited an adverse property. Despite an ability to provoke large increases in blood flow to the gut, papaverine caused a decrease in intestinal oxygen consumption in the normotensive animal. When the dogs were shocked with gram negative endotoxin, thereby producing profound ischemia and greatly reduced oxygen uptake by the gut, infusion of papaverine into the mesenteric artery further lowered oxygen uptake by the hypoxic intestine [7] .
By contrast, intraarterial infusion of prostaglandin El induced not only a pronounced increase in mesenteric blood flow and a nearly equal increase in intestinal oxygen consumption in either normotensive or shocked dogs [6, 8, 9] . The dose of prostaglandin E1 needed to elicit such responses was 0.1 ug/kg-min. Because of its rapid metabolism to inactive forms by 15 prostaglandin dehydrogenase in the gut wall, liver and lung, intraarterial infusion of prostaglandin Ei was not associated with any systemic arterial depressor effect. Prostaglandin El has also been shown to stabilize lysosomal membranes and to antagonize platelet aggregation. Recently we have employed prostaglandin Ei as a pharmacoangiographic aid in visualizing mesenteric and portal vessels in dogs [10] and in patients undergoing diagnostic angiography. A single dose of 7.5 ug injected into the superior mesenteric artery 15 seconds before injection of the contrast medium greatly enhanced visualization of both arterial and venous phases of the angiogram in our clinical trials of the drug.
Given the many dilator drugs which are available, it would appear that further comparative studies are warranted. Such investigations should utilize sub human primate models where feasible. The ability of the interventional radiologist to insert a catheter into any sizable vessel offers the opportunity to deliver potent and selective agents to manipulate blood flow in desired directions in order to reverse the course of life-threatening vascular diseases.
